Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively new class of drugs that work by suppressing appetite and food intake. They’ve been hailed as not only life ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.